Biomedical Engineering Reference
In-Depth Information
113. Leppanen M, Korpi A, Miettinen M, Leskinen J, Torvela T, Rossi EM et al. Nanosized TiO(2) caused
minor airflow limitation in the murine airways. Archives of Toxicology . 2011;85:827-39.
114. Koike E, Kobayashi T. Chemical and biological oxidative effects of carbon black nanoparticles.
Chemosphere . 2006;65:946-51.
115. Muhlfeld C, Geiser M, Kapp N, Gehr P, Rothen-Rutishauser B. Re-evaluation of pulmonary titanium
dioxide nanoparticle distribution using the “relative deposition index”: Evidence for clearance through
microvasculature. Particle and Fibre Toxicology . 2007;4:7.
116. Olmedo D, Guglielmotti MB, Cabrini RL. An experimental study of the dissemination of titanium and
zirconium in the body. Journal of Materials Science Materials in Medicine . 2002;13:793-6.
117. Berry JP, Arnoux B, Stanislas G, Galle P, Chretien J. A microanalytic study of particles transport across
the alveoli: Role of blood platelets. Biomedicine/[publiee pour l'AAICIG] . 1977;27:354-7.
118. Nemmar A, Vanbilloen H, Hoylaerts MF, Hoet PH, Verbruggen A, Nemery B. Passage of intratracheally
instilled ultrafine particles from the lung into the systemic circulation in hamster. American Journal of
Respiratory and Critical Care Medicine . 2001;164:1665-8.
119. Shimada M, Wang WN, Okuyama K, Myojo T, Oyabu T, Morimoto Y et al. Development and evaluation
of an aerosol generation and supplying system for inhalation experiments of manufactured nanoparticles.
Environmental Science & Technology . 2009;43:5529-34.
120. Christensen FM, Johnston HJ, Stone V, Aitken RJ, Hankin S, Peters S et al. Nano-TiO(2)—Feasibility and
challenges for human health risk assessment based on open literature. Nanotoxicology . 2011;5:110-24.
121. Moebus K, Siepmann J, Bodmeier R. Cubic phase-forming dry powders for controlled drug delivery
on mucosal surfaces. Journal of Controlled Release: Official Journal of the Controlled Release Society .
2012;157:206-15.
122. Li FQ, Hu JH, Lu B, Yao H, Zhang WG. Ciprofloxacin-loaded bovine serum albumin microspheres:
Preparation and drug-release in vitro . Journal of Microencapsulation . 2001;18:825-9.
123. Sugio S, Kashima A, Mochizuki S, Noda M, Kobayashi K. Crystal structure of human serum albumin at
2.5 A resolution. Protein Engineering . 1999;12:439-46.
124. He XM, Carter DC. Atomic structure and chemistry of human serum albumin. Nature . 1992;358:209-15.
125. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine.
Advanced Drug Delivery Reviews . 2008;60:876-85.
126. Paal K, Muller J, Hegedus L. High affinity binding of paclitaxel to human serum albumin. European
Journal of Biochemistry/FEBS . 2001;268:2187-91.
127. Purcell M, Neault JF, Tajmir-Riahi HA. Interaction of taxol with human serum albumin. Biochimica et
Biophysica Acta . 2000;1478:61-8.
128. Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, Langer K. Highly specific HER2-
mediated cellular uptake of antibody-modified nanoparticles in tumour cells. Journal of Drug Targeting .
2004;12:461-71.
129. Weber C, Coester C, Kreuter J, Langer K. Desolvation process and surface characterisation of protein
nanoparticles. International Journal of Pharmaceutics . 2000;194:91-102.
130. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. Optimization of the prepara-
tion process for human serum albumin (HSA) nanoparticles. International Journal of Pharmaceutics .
2003;257:169-80.
131. Minshall RD, Sessa WC, Stan RV, Anderson RG, Malik AB. Caveolin regulation of endothelial function.
American Journal of Physiology Lung Cellular and Molecular Physiology . 2003;285:L1179-83.
132. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane
ABI-007) in the treatment of breast cancer. International Journal of Nanomedicine . 2009;4:99-105.
133. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A et  al. Increased antitumor activity, intratumor pacli-
taxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-
007, compared with cremophor-based paclitaxel. Clinical Cancer Research: An Official Journal of the
American Association for Cancer Research . 2006;12:1317-24.
134. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A et al. Comparative preclinical and clini-
cal pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and pacli-
taxel formulated in Cremophor (Taxol). Clinical Cancer Research: An Official Journal of the American
Association for Cancer Research . 2005;11:4136-43.
135. Wang C, Wu QH, Li CR, Wang Z, Ma JJ, Zang XH et al. Interaction of tetrandrine with human serum
albumin: A fluorescence quenching study. Analytical Sciences: The International Journal of the Japan
Society for Analytical Chemistry . 2007;23:429-33.
136. Peterson C, Neal JH, Cotman CW. Development of N -methyl-d-aspartate excitotoxicity in cultured hip-
pocampal neurons. Brain Research Developmental Brain Research . 1989;48:187-95.
Search WWH ::




Custom Search